Health and Global Policy Institute (HGPI) supports the promotional activity of NCD control by placing its focus on cardiovascular disease, diabetes, chronic respiratory disease, cancer and mental health illness.
As the medical costs to combat NCDs is soaring with an underline issue of aging society, a new strategy is needed for the future that goes beyond tackling and treating individual diseases.
Therefore HGPI cooperate with domestic and international stakeholders including the NCD Alliance, we moved forward with the establishment of NCD Alliance Japan as a forum for sharing and discussing international knowledge on NCDs. (http://ncdjapan.org/en/)
NCD Alliance Japan aims to contribute to the promotion of comprehensive cross-disease measures through discussion with multiple stakeholders involved with each respective disease.
This forum aims to clarify the strength of Japan in NCD control, and discussed how Japan can contribute to the International NCD control.

[Forum Details]
■Date: 2013.11.30 (Sat) 10:00-12:30
■Place: Academy Hills Tower Hall B (6-10-1 Roppongi, Minato-ku, Tokyo)
■Participants: Related ministry officials, embassy officials, medical personnel, healthcare companies, healthcare policy and NCD control specialists, major media, journalists etc.
■Program: ※title omitted

1.Opening Remarks (10:00 – 10:05)
　・Kiyoshi Kurokawa(Chairman, HGPI)

2.Session 1: Japan’s strength in NCD that empowers the world(10:10-10:55)
Explore the strength of Japan for international expansion by looking back at the NCD related measures in Japan.
・Tastuya Kondo(Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA))
“International harmonization of regulatory science”
・Shiro Konuma(Director, Global Health Policy Division, the Ministry of Foreign Affairs of Japan / Member, The Global Health Innovative Technology Fund (GHIT Fund))
“The possibility of having an insurance system that allows all citizens to be covered in overseas as in Japan”
・Eriya Kitano (Executive Director, Medical Excellence JAPAN)
“Overseas expansion of medical technology in Japan”
・Risa Nakamura (Program coordinator, United Nations Development Programme in Chad office)(Moderator)
・Toshio Miyata (Executive Director, HGPI / Special Advisor to the Cabinet about Health Care and Research Strategy ) (Moderator)


3.Session 2: To contribute to NCD control at a global level (11:00-11:45)
Introducing the success stories from overseas, understanding current issues and the secret of success
・Yoshiki Sawa (Professor and chief, Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
“Overseas expansion of regenerative medicine in Japan”
・Yasuhiro Fujiwara(Director-General, Strategic Planning Bureau, National Cancer Center)
“Overseas expansion of Japan cancer healthcare”
・Masafumi Nogimori (Representative Director and Chairman, Astellas Pharma Inc. / Vice President, Japan Pharmaceutical Manufacturers Association(JPMA))
“The role of the pharmaceutical industry in NCD measures: – the responsibilities of partnership in health and medical care”
・Risa Nakamura (Program coordinator, United Nations Development Programme in Chad office)(Moderator)
・Toshio Miyata (Executive Director, HGPI / Special Advisor to the Cabinet about Health Care and Research Strategy ) (Moderator)

4.Special Remark
・Hidehito Sekino (Director,　Office　of　Medical　Devices　Policy Health, Policy　Bureau, Ministry of Health, Labour and Welfare)
　
５.Panel Discussion – The role of Japan in International NCD control (11:50-12:20)
Discussion of the role of Japan in International NCD control and how Japan’s experience can be fully utilized base on the discussions in session 1 and 2
・Tastuya Kondo(Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA))
・Shiro Konuma(Director, Global Health Policy Division, the Ministry of Foreign Affairs of Japan / Member, The Global Health Innovative Technology Fund (GHIT Fund))
・Eriya Kitano (Executive Director, Medical Excellence JAPAN)
・Yoshiki Sawa (Professor and chief, Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)
・Yasuhiro Fujiwara (Director-General, Strategic Planning Bureau, National Cancer Center)
・Masafumi  Nogimori (Representative Director and Chairman, Astellas Pharma Inc. / Vice President, Japan Pharmaceutical Manufacturers Association(JPMA))
・Hidehito Sekino (Director,　Office　of　Medical　Devices　Policy Health, Policy　Bureau, Ministry of Health, Labour and Welfare)
・Risa Nakamura (Program coordinator, United Nations Development Programme in Chad office)(Moderator)
・Toshio Miyata (Executive Director, HGPI / Special Advisor to the Cabinet about Health Care and Research Strategy ) (Moderator)


6.Closing Remarks: The effort of NCD Alliance Japan (12:25-12:30)
　・Toshio Miyata (Executive Director, HGPI / Special Advisor to the Cabinet about Health Care and Research Strategy ) (Moderator)


About Health and Global Policy Institute:   
 
Since establishment, Health and Global Policy Institute has been working to help citizens shape health policies by generating policy options, and to bring stakeholders together as a non-partisan think-tank, as is stipulated in the mission statement. One of the Institute’s guiding principles is independence, not to be restricted by interests of any organization or political party. The Institute will continue to maintain political neutrality and independence from any organization in conducting its activities.
For more information, please visit at http://www.hgpi.org/en/

About NCD Alliance:
 
The NCD Alliance is a global partnership formed originally by 4 international federations: the International Diabetes Federation, Union for International Cancer Control, World Heart Federation, and International Union Against Tuberculosis and Lung Disease. Uniting a network of over 2,000 civil society organizations in more than 170 countries, the NCD Alliance’s mission is to combat the NCD epidemic by putting health at the center of all policies.
For more information, please visit at http://ncdalliance.org/

Registration deadline: 2013-11-29

Exhibition date：2013-11-30